Personal Statements
Dr. Achille Manirakiza is an early-career Clinical Oncologist having worked at the first radiotherapy center in Kigali, Rwanda, after completing his residency in Clinical Oncology at the Muhimbili University of Health and Allied Sciences in 2018. He currently leads the Oncology Unit at the King Faisal Hospital, in Kigali. His research work has been focused on gynecological malignancies treatment outcomes in Low-Income Countries, contributing to knowledge in the global cancer treatment access movement, and medical/oncology education in general.
He has developed, over time, a great interest in cancer genetics, particularly related to genital-urinary malignancies. Notable, ongoing projects are under the Men of African Descent Carcinoma Prostate consortium, a study on PSA cost-effectiveness in Africa, and disease databases development of patients treated at the radiation center in Kigali. In the same realm, he intends to focus his future research work in the relatively less known area of genital-urinary malignancies epidemiology, with a special interest in castrate-resistant prostate cancer, the correlation between prostate cancer genetics and its incidence and treatment outcomes in Rwanda, under the mentorship of Prof Timothy Rebbeck at the Dana Farber Cancer Institute, Harvard School of Public Health and Prof Leon Mutesa at the University of Rwanda.
Positions and Honors:
Positions
- October 7th 2013- November 30th 2014: Intern Doctor at Ruhengeri Provincial Hospital
- December 1st 2014 – September 15th 2015: Medical Officer at the Rwanda Ministry of Health
- November 2015- December 2018: Resident – Clinical Oncology Department, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania
- January 2019 – Present: Clinical Oncologist, Rwanda Military Hospital Radiotherapy Centre, Kigali, Rwanda.
- January 2019 – Present: Visiting Clinical Oncologist, King Faisal Hospital, Kigali, Rwanda
Honors
- Pediatric Global Oncology and Blood Disorders Education (GLOBE) award – Dana Farber, Boston, MA, October 2016;
- Union for International Cancer Control – Technical Fellowship (UICC-TF) award – Dana Farber, Boston, MA, October 2017;\
- African Cancer Leadership Institute Award – African Organization of Research and Treatment In Cancer (AORTIC), November 2017
- POETIC fellowship award– Massachusetts General Hospital, Boston, MA, September – October 2018;
- International Psycho-Oncology Society (IPOS) Research Academy & World Congress Travel Grant award – Hong Kong, China, November 2018
- Mayo Clinic Inaugural Resident Exchange – Mayo Clinic, Rochester, MN, November 2018
Contributions to Science
Van Essen C, Cartledge P, Kyamanywa P, Manirakiza A. Is HINARI appropriate for medical students in the developing world? Tropical Medicine & International Health. 2012 Apr;17(4):406-8.Manirakiza A, Longombe AN, Kyamanywa P, Rulisa S. Cervical cancer in Rwanda: Why do women consult in late stages? Rwanda Medical Journal. 2016 Dec;73(4):9-11.
Rubagumya F, Greenberg L, Manirakiza A, DeBoer R, Park PH, Mpunga T, Shulman LN. Increasing global access to cancer care: models of care with non-oncologists as primary providers. The Lancet Oncology. 2017 Aug 1; 18(8):1000-2.
Manirakiza A, Sinha S, Rubagumya F. Locally Advanced Cervical Carcinoma Management., InTech Open, 2018
Manirakiza A, Hrdy M, Ginwalla R, Kamanzi B, Calland JF. Mentorship Role in the choice of surgery as a career among medical students in Rwanda, Rwanda Medical Journal, Vol. 73, No. 3, 2016, pp. 17-20
Additional Information: Research Support and/or Scholastic Performance
ACTIVE
Code: 12665 (Rubagumya)
ASCO – Conquer Cancer Foundation – International Innovation Grant
Use of smart phone application for early detection of skin cancers in people with albinism
Validation of a smart phone application in skin cancer detection for people living with albinism in Tanzania
Role: Co-PI
INSTITUTION AND LOCATION | DEGREE
(if applicable) |
Completion Date
MM/YYYY |
FIELD OF STUDY |
---|---|---|---|
|
Medical Doctor | 08/2013 | School of Medicine |
|
Masters of Medicine | 12/2018 | Clinical Oncology |